Last updated: September 9, 2026
Ioversol is a mature, off-patent iodinated contrast agent sold primarily under the Optiray brand. Guerbet controls the principal U.S. commercial rights after acquiring Mallinckrodt’s contrast-media business. Its market position depends on hospital contracts, radiology utilization, supply reliability, pricing, and portfolio relationships rather than on exclusivity. Public companies do not report ioversol revenue as a separate line item, so an exact product-level financial trajectory is unavailable. The commercial outlook is stable but low-growth, with upside from procedure volumes and downside from generic competition, procurement pressure, and substitution by competing contrast agents.
What is ioversol and how is it used?
Ioversol is a nonionic, low-osmolar, water-soluble iodinated contrast medium. It is administered intravenously or intra-arterially to improve visualization during diagnostic imaging.
| Attribute |
Ioversol |
| Primary brand |
Optiray |
| Main U.S. commercial company |
Guerbet |
| Drug class |
Nonionic, low-osmolar iodinated contrast medium |
| Administration |
Intravenous and intra-arterial |
| Common concentrations |
240, 300, 320, and 350 mg iodine/mL |
| Major uses |
CT imaging, cerebral angiography, peripheral angiography, coronary angiography, intravenous digital subtraction angiography, and excretory urography |
| Regulatory status |
FDA-approved contrast agent |
| Commercial maturity |
Mature, off-patent injectable product |
| Primary customers |
Hospitals, outpatient imaging centers, radiology groups, and distributors |
Optiray products are differentiated mainly by iodine concentration, viscosity, indication coverage, packaging, and supply performance. Clinical switching costs are limited because radiology departments can often substitute another nonionic iodinated contrast agent subject to protocol, formulary, and procurement requirements.
Who manufactures and markets ioversol?
Guerbet is the principal company associated with Optiray and ioversol in the United States. Guerbet acquired Mallinckrodt’s contrast-media and delivery-systems business in 2015, expanding its position in diagnostic imaging products.[1]
The broader ioversol supply chain includes active pharmaceutical ingredient manufacturers, sterile injectable contract manufacturers, packaging suppliers, distributors, and hospital group purchasing organizations. Manufacturing capability is commercially important because contrast media require validated sterile production, high-purity iodine chemistry, quality controls, and specialized filling operations.
What products compete with Optiray?
Ioversol competes with several established iodinated contrast agents:
| Active ingredient |
Representative brands |
Principal companies |
| Ioversol |
Optiray |
Guerbet |
| Iohexol |
Omnipaque |
GE HealthCare |
| Iopamidol |
Isovue |
Bracco |
| Iopromide |
Ultravist |
Bayer |
| Iodixanol |
Visipaque |
GE HealthCare |
| Ioxilan |
Oxilan |
Generic and regional suppliers |
Competition is generally based on total procedure cost, supply continuity, injector compatibility, clinical familiarity, reimbursement economics, and hospital contracts. Ioversol has no clear product-level differentiation that would support premium pricing across the entire market.
How large is the ioversol market?
No major public company reports global ioversol sales separately. Available financial disclosures generally combine ioversol with other contrast agents, imaging products, or regional business units. Market-research estimates for the standalone ioversol market are therefore less reliable than estimates for the broader iodinated contrast-media market.
The relevant market is the global nonionic iodinated contrast-media segment. Demand is tied to:
- CT scan volumes.
- Cardiovascular and peripheral angiography.
- Cancer diagnosis and monitoring.
- Emergency-department imaging.
- Aging populations.
- Expansion of imaging infrastructure in emerging markets.
- Hospital replacement of older ionic or higher-osmolar agents.
Volume growth is likely to be modest in mature markets. Pricing is constrained by group purchasing organizations, tenders, generic entrants, and hospital budget controls. Growth can be stronger in developing markets, but local registration, manufacturing, reimbursement, and distribution requirements limit rapid expansion.
What is the financial trajectory for ioversol?
Ioversol is best characterized as a mature cash-generation product rather than a high-growth pharmaceutical asset. Its financial trajectory has four phases:
| Period |
Financial pattern |
Main drivers |
| Launch and expansion |
Stronger growth and pricing |
New approvals, adoption by radiology departments, brand establishment |
| Maturity |
Stable or declining unit pricing |
Generic entry, tender competition, formulary substitution |
| Supply-disruption period |
Volatile revenue and margins |
Manufacturing interruptions, inventory shortages, emergency procurement |
| Long-term mature phase |
Low-single-digit volume growth or flat sales |
Imaging utilization, contract renewals, price erosion, portfolio bundling |
Guerbet’s public reporting aggregates contrast-media revenue and does not isolate Optiray or ioversol. As a result, product-level revenue, gross margin, and annual growth cannot be calculated from public filings without proprietary prescription, tender, or shipment data.[2]
The strongest financial variables are:
- U.S. hospital contract retention.
- Availability of all Optiray concentrations.
- Manufacturing cost per vial.
- Price concessions to group purchasing organizations.
- Share retained against Omnipaque, Isovue, Ultravist, and generic ioversol.
- Procedure-volume growth in CT and angiography.
- Distribution and inventory costs.
Ioversol likely produces recurring revenue because hospitals use contrast agents continuously. The product does not require chronic patient adherence, and revenue is linked to procedure volume rather than prescription refills.
When does ioversol lose exclusivity?
Ioversol’s principal commercial exclusivity has already expired. Optiray was approved decades ago, and the active-ingredient and core product patent barriers are not expected to prevent generic competition.
The commercial loss of exclusivity has several consequences:
- Multiple manufacturers can compete on price.
- Hospitals can substitute other iodinated contrast agents.
- A brand premium is difficult to sustain.
- Product availability and contract execution become more important than patent rights.
- Regulatory and manufacturing capabilities replace patent protection as the main barriers to entry.
Ioversol is not comparable to a recently approved small-molecule medicine with a long remaining patent term. Its defensibility comes from manufacturing scale, regulatory history, supply reliability, customer relationships, and bundled imaging offerings.
What is the Orange Book status of ioversol?
Optiray is an FDA-approved prescription diagnostic product, but its commercial status is different from that of a modern branded therapeutic drug with extensive Orange Book patent listings. Publicly available FDA labeling identifies Optiray formulations and indications, while the product’s practical market protection is not based on an active composition-of-matter patent estate.[3]
No significant active patent barrier is generally associated with the commercial use of ioversol in standard Optiray concentrations. Generic approval depends primarily on the applicable FDA abbreviated or supplemental pathway, product quality, bioequivalence or performance requirements, facility compliance, and sterile manufacturing controls.
What patents protect ioversol and its formulations?
The early ioversol patent estate covered the compound, iodinated benzoic-acid chemistry, pharmaceutical compositions, and contrast-media formulations. Those rights are legacy protections and are not expected to provide meaningful remaining exclusivity for ordinary ioversol products.
Potentially relevant intellectual-property categories include:
| IP category |
Commercial relevance today |
| Ioversol compound patents |
Expired or commercially exhausted |
| Pharmaceutical composition patents |
Expired or weak against standard generic formulations |
| Concentration-specific formulations |
Limited protection if any relevant rights remain |
| Container and packaging patents |
Narrow and readily designed around |
| Injector and delivery-system IP |
More relevant to equipment than to ioversol itself |
| Manufacturing know-how |
Commercially important but difficult to assess publicly |
| Trade secrets |
May affect cost and yield, not market exclusivity |
Formulation patents would have greater value if they covered a meaningful stability, viscosity, container, or delivery improvement that competitors could not readily reproduce. Standard Optiray concentrations do not appear to have a high-value, long-duration formulation moat.
Are there Paragraph IV challenges to ioversol?
Paragraph IV litigation is not a central current risk driver for ioversol. The product is old, generic competition is established, and any historical patent-certification disputes would have limited effect on present-day market access.
The more relevant regulatory risk is an abbreviated application or other generic approval that increases price competition. A successful generic entrant would normally affect contract pricing and share rather than trigger a single discrete patent cliff.
What FDA regulatory issues affect ioversol?
FDA regulation focuses on sterile manufacturing, finished-product quality, labeling, adverse-event monitoring, facility compliance, and the safe use of iodinated contrast media.
Important label risks include:
- Severe hypersensitivity reactions.
- Acute kidney injury risk in susceptible patients.
- Extravasation during injection.
- Thyroid dysfunction in vulnerable patients.
- Cardiovascular and neurologic complications during angiography.
- Dosing and concentration selection by imaging procedure.
The product’s established safety history supports continued use, but manufacturing interruptions can create immediate commercial consequences. Contrast media are administered in hospitals and imaging centers under time-sensitive conditions. A shortage can shift demand quickly to Omnipaque, Isovue, Ultravist, Visipaque, or other available products.
What generic entry risks exist for Optiray?
Generic entry risk is high in principle but moderate in incremental impact because ioversol already competes in a mature market. The main risks are:
- Lower contract prices.
- Loss of preferred formulary status.
- Substitution by lower-cost ioversol suppliers.
- Reduced utilization of brand-labeled Optiray.
- Distributor destocking.
- Margin compression for the originator.
- Greater dependence on manufacturing efficiency.
A generic manufacturer still faces meaningful barriers. Ioversol is an injectable contrast medium, so entrants need validated sterile facilities, reliable supply of pharmaceutical-grade raw materials, FDA-compliant processes, appropriate packaging, and hospital-quality documentation. These requirements slow entry but do not create durable brand protection.
How does ioversol compare with iohexol and iopamidol?
| Factor |
Ioversol |
Iohexol |
Iopamidol |
| Major brand |
Optiray |
Omnipaque |
Isovue |
| Market age |
Mature |
Mature |
Mature |
| Primary commercial strength |
Guerbet imaging portfolio |
GE HealthCare scale and broad adoption |
Bracco radiology portfolio |
| Clinical substitution |
High |
High |
High |
| Patent protection |
No meaningful modern exclusivity |
No meaningful modern exclusivity |
No meaningful modern exclusivity |
| Main competitive lever |
Price, availability, contracts |
Scale, availability, contracts |
Clinical familiarity, contracts, availability |
| Financial outlook |
Stable mature product |
Stable mature product |
Stable mature product |
Ioversol’s competitive position is strongest where Guerbet has favorable hospital contracts, dependable inventory, and a broader relationship with radiology departments. It is weaker where procurement teams consolidate purchases around a single large supplier or where competitors offer broader injector, software, and contrast portfolios.
What licensing deals and transactions affect ioversol?
The most important disclosed transaction is Guerbet’s acquisition of Mallinckrodt’s contrast-media and delivery-systems business. The transaction transferred the commercial platform associated with Optiray and related products to Guerbet.[1]
No major recent licensing transaction is necessary to explain ioversol’s market position. The product is commercially managed as part of an established imaging portfolio rather than as a newly licensed growth asset.
What patent litigation affects ioversol?
No major active patent litigation is central to the current ioversol commercial outlook. Litigation risk is more likely to involve:
- Generic approval disputes.
- Product-liability claims.
- Manufacturing or supply agreements.
- Distribution contracts.
- Regulatory enforcement.
- Hospital procurement disputes.
Patent litigation is unlikely to restore meaningful exclusivity because the foundational rights protecting ioversol are old and the product has long operated in a competitive market.
What is the outlook for ioversol revenue?
The base case is stable mature revenue with limited pricing growth. Volume may rise with CT and angiography utilization, but unit prices will remain under pressure.
| Scenario |
Revenue direction |
Key conditions |
| Base case |
Flat to modest growth |
Stable imaging volumes and contract retention |
| Upside case |
Moderate growth |
Supply shortages at competitors, stronger emerging-market demand, higher procedure volumes |
| Downside case |
Decline |
Generic price competition, contract loss, manufacturing disruption, or substitution by competing agents |
Ioversol’s revenue exposure is more operational than intellectual-property driven. The value of the product depends on dependable production, broad regulatory coverage, competitive tenders, and continued inclusion in hospital formularies.
Key Takeaways
- Ioversol is a mature, off-patent iodinated contrast medium marketed mainly as Optiray.
- Guerbet is the principal U.S. commercial company after acquiring Mallinckrodt’s contrast-media business.
- Public filings do not disclose standalone ioversol revenue or profit.
- The product’s financial trajectory is likely stable to modestly declining in price, with volume linked to imaging utilization.
- Patent protection is not the main commercial barrier.
- Generic entry risk is real, but sterile manufacturing and hospital procurement requirements limit rapid disruption.
- The main competitors are iohexol, iopamidol, iopromide, iodixanol, and ioxilan products.
- Supply reliability, hospital contracts, and manufacturing economics matter more than patent litigation.
- The FDA regulatory risk profile is driven by injectable-product quality, hypersensitivity, renal, thyroid, and administration-related safety issues.
- Ioversol is a recurring-revenue diagnostic product, not a high-growth branded therapeutic.
FAQs
Is ioversol still patent protected?
No meaningful modern exclusivity is expected to protect standard ioversol products. The compound and core formulation protections are legacy rights.
Is Optiray a generic drug?
Optiray is the branded ioversol product. Ioversol itself is the active ingredient and can be supplied by generic or regional manufacturers subject to FDA or other national regulatory requirements.
Who owns Optiray?
Guerbet controls the principal commercial rights associated with Optiray in the United States following its acquisition of Mallinckrodt’s contrast-media business.
Can hospitals substitute iohexol for ioversol?
Yes. Hospitals can often substitute another nonionic iodinated contrast agent, subject to clinical protocols, formulary rules, injector compatibility, supply, and procurement contracts.
Is ioversol a biologic or biosimilar product?
No. Ioversol is a chemically synthesized small-molecule contrast agent. Biosimilar regulation does not apply.
Does ioversol have significant manufacturing barriers?
Yes. Sterile injectable production, raw-material quality, validated filling operations, regulatory compliance, and hospital supply requirements create entry barriers even though patent protection is limited.
What would most increase ioversol sales?
Higher CT and angiography volumes, competitor supply disruptions, successful hospital-contract renewals, expanded international distribution, and stronger availability across Optiray concentrations would have the greatest effect.
References
- Guerbet. (2015). Guerbet announces the completion of the acquisition of Mallinckrodt’s contrast media and delivery systems business. https://www.guerbet.com
- Guerbet. (2023). Universal registration document and annual financial report 2023. https://www.guerbet.com/investors
- U.S. Food and Drug Administration. (n.d.). Optiray (ioversol) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- Guerbet. (2024). Annual financial information and investor publications. https://www.guerbet.com/investors
